Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis.
Sign Up to like & getrecommendations! Published in 2022 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2022.103669
Abstract: BACKGROUND Lymphopenia is a major concern in MS patients treated with dimethyl-fumarate (DMF) as it increases the risk of progressive multifocal leukoencephalopathy. A pronounced reduction in absolute lymphocyte counts (ALCs) early after treatment initiation has… read more here.
Keywords: risk; dimethyl fumarate; predictive risk; alcs ... See more keywords